Daniel Lee
Neurology · Mobile, ALNPI 1811566532
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,995, more than ten times the $42 reported in 2022.
Across 131 payments — averaging $29.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$417
- SK Life Science, Inc.$416
- AstraZeneca$393
- AbbVie$318
- Acadia Pharmaceuticals Inc$257
- Merz Pharmaceuticals, LLC$245
- plus $2K from 20 others
What the payments were for
- Food & beverage$3,807100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 18 | $417 |
| SK Life Science, Inc. | 14 | $416 |
| AstraZeneca(2 entities) | 13 | $393 |
| AbbVie | 9 | $318 |
| Acadia Pharmaceuticals Inc | 11 | $257 |
| Merz Pharmaceuticals, LLC | 4 | $245 |
| Novartis | 10 | $225 |
| Jazz Pharmaceuticals Inc. | 6 | $219 |
| Teva Pharmaceuticals USA, Inc. | 3 | $195 |
| Amgen | 3 | $164 |
| Neurocrine Biosciences, Inc. | 6 | $163 |
| EMD Serono, Inc. | 2 | $99 |
| Genentech USA, Inc. | 4 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $94 |
| Biogen | 3 | $73 |
| Argenx US, Inc. | 3 | $64 |
| Tanabe Pharma America, Inc. | 4 | $62 |
| Azurity Pharmaceuticals, Inc. | 2 | $49 |
| Upsher-smith Laboratories LLC | 2 | $47 |
| Grifols USA, LLC | 2 | $45 |
| Lundbeck LLC | 2 | $42 |
| Johnson & Johnson | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| PTC Therapeutics, Inc. | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$164
- Austedo XR$130
- VYALEV$123
- Epidiolex$119
How this compares
$3,807 in reported general payments places this provider in the 55th percentile of 255 neurology providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 15 | $974 |
Paid to pharmacies, not to this prescriber.
Other neurology in Mobile
- Daniel DeesMobile$799K
- Hayden LongMobile$386K
- Charles MarkleMobile$212K
- William KilgoMobile$200K
- Bassam BassamMobile$197K
- Dean NaritokuMobile$160K
- Steve CordinaMobile$69K
- Thomas FosterMobile$51K
- Laura MintoMobile$33K
- Andrew ManleyMobile$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.